CIK 0001789972
- Non-accelerated filer
- Smaller reporting company
Cullinan Therapeutics, Inc.
Sign in to watch- Ticker
- CGEM
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 813879991
- Phone
- +1 617-410-4650
- Business address
- ONE MAIN STREET, SUITE 1350, CAMBRIDGE, MA, 02142
- Former names
- Cullinan Oncology, Inc., Cullinan Management, Inc., Cullinan Oncology, LLC
- 4 Open-market sale Chief Scientific Officer sold 1,145 shares at $8.50 ($9,733)
- 4 Open-market sale Chief Medical Officer sold 386 shares at $8.22 ($3,173)
- 4 Open-market sale Chief Scientific Officer sold 238 shares at $8.22 ($1,956)
- 4 Open-market sale Chief Legal Officer sold 290 shares at $8.22 ($2,384)
- 4 Open-market sale Chief Financial Officer sold 398 shares at $8.22 ($3,272)
- 4 Open-market sale Chief Financial Officer sold 1,926 shares at $7.81 ($15,042)
- 4 Open-market sale Chief Scientific Officer sold 1,068 shares at $7.81 ($8,341)
- 4 Grant or award Chief Financial Officer acquired 2,340 shares (grant or award)
- 4 Open-market sale President and CEO sold 759 shares at $11.40 ($8,653)
- 4 Open-market sale Chief Medical Officer sold 387 shares at $12.94 ($5,008)
- 4 Open-market sale Chief Development Officer sold 238 shares at $12.94 ($3,080)
- 4 Open-market sale Chief Financial Officer sold 399 shares at $12.94 ($5,163)
- 4 Open-market sale Chief Legal Officer sold 291 shares at $12.94 ($3,766)
- 4 Open-market sale Chief Financial Officer sold 319 shares at $13.11 ($4,182)
- 4 Open-market sale Chief Development Officer sold 176 shares at $13.11 ($2,307)
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Planned sale Chief Development Officer sold 12,000 shares at an average $12.31 ($147,729)
Page 6 of 13 · 253 filings